Journal article
Platelet-derived growth factor-AB improves scar mechanics and vascularity after myocardial infarction
S Thavapalachandran, SM Grieve, RD Hume, TYL Le, K Raguram, JE Hudson, J Pouliopoulos, GA Figtree, RP Dye, AM Barry, P Brown, J Lu, S Coffey, SH Kesteven, RJ Mills, FN Rashid, E Taran, P Kovoor, L Thomas, AR Denniss Show all
Science Translational Medicine | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2020
Abstract
Therapies that target scar formation after myocardial infarction (MI) could prevent ensuing heart failure or death from ventricular arrhythmias. We have previously shown that recombinant human platelet-derived growth factor-AB (rhPDGF-AB) improves cardiac function in a rodent model of MI. To progress clinical translation, we evaluated rhPDGF-AB treatment in a clinically relevant porcine model of myocardial ischemia-reperfusion. Thirty-six pigs were randomized to sham procedure or balloon occlusion of the proximal left anterior descending coronary artery with 7-day intravenous infusion of rhPDGF-AB or vehicle. One month after MI, rhPDGF-AB improved survival by 40% compared with vehicle, and c..
View full abstractGrants
Awarded by Heart Research Australia
Funding Acknowledgements
The study was funded by the National Heart Foundation Australia (NHF) Cardiovascular Research Network Grant (100711) and by National Health and Medical Research Council (NHMRC) project grants (1126277 and 1100046). J.J.H. C. was supported by a Future Leader Fellowship (100463) from the NHF Australia and a Sydney Medical School Foundation Fellowship. S.T. was supported by a Westmead Medical Research Foundation Scholarship (The Stephen and Barbara Penfold PhD Scholarship) and a cofunded postgraduate scholarship from the NHF Australia (101108) and NHMRC (1114472). S.M.G. acknowledges the support of the Parker Hughes Bequest. J.E.H. acknowledges funding from QIMR Berghofer Medical Research Institute, project support from NHF Australia, and fellowships and grants from the NHMRC. S.C. was supported by a scholarship from Heart Research Australia. R.P.H. received funding from the Australian Research Council Strategic Initiative in Stem Cell Science (110001002), NHMRC Program Grant (1074386), NHMRC Australia Fellowship (573705), NHMRC Senior Principal Research Fellowship (1118576), Foundation Leducq Transatlantic Network of Excellence in Cardiovascular Research (13CVD01, 15CVD03), and the Australia India Strategic Research Fund (BF020084, BF050024).